PET/MR Could Be Effective for Staging Esophageal Cancer

Article

Preoperative staging of esophageal cancer with PET/MR is approximately as good as with endoscopic ultrasound, and may improve slightly over ultrasound and PET/CT scans, according to a new study.

Esophageal cancer as seen on CT

Esophageal cancer as seen on CT; source: Hellerhoff, Wikimedia Commons

Preoperative staging of esophageal cancer with the new imaging modality PET/MR is approximately as good as with endoscopic ultrasound, and may improve slightly over ultrasound and PET/CT scans, according to a new study published in the Journal of Nuclear Medicine on May 27.

“Accurate staging of esophageal cancer is critical for decisions on patient treatment,” wrote study authors led by Geewon Lee, MD, of Pusan National University Hospital in Busan, South Korea. Current guidelines recommend CT of the chest and abdomen along with endoscopic ultrasound (EUS) and PET/CT. “The recently available hybrid modality PET/MR imaging allows combination of both metabolic and anatomic information about the cancer.” To assess this new modality, the researchers compared PET/MR with EUS, CT, and PET/CT in esophageal cancer staging.

Over the course of 1 year, 19 patients with resectable esophageal cancer underwent preoperative imaging with all four of the imaging modalities, and tumor and lymph node stages were assigned. Four of the patients were subsequently treated non-surgically, and were thus excluded from the analysis.

The primary tumors were correctly staged in 13 patients (86.7%) using EUS, in 10 patients (66.7%) using PET/MR, and in five patients (33.3%) using CT scanning. EUS was significantly better than CT (P = .021), though no better than PET/MR (P = .375). PET/MR just failed to reach significance over CT imaging (P = .063).

EUS was still best with regard to determining T1 lesions, at 86.7%. PET/MR had an accuracy of 80% while CT had an accuracy of 46.7%. EUS was also better at distinguishing T3 lesions, at 93.3% accuracy; PET/MR and CT were both 86.7%.

With regard to lymph node staging, PET/MR outperformed the other modalities. Lymph node staging accuracy was 83.3% with PET/MR compared with 75% for EUS, 66.7% for PET/CT, and 50% for CT scanning. “Accurate N staging is essential, as it is a known prognostic factor associated with overall survival,” the authors wrote. “MR imaging offers the advantages of excellent soft-tissue contrast and lack of exposure to ionizing radiation.”

The authors did note the small number of patients as a limitation to the study’s interpretation, as well as the inclusion of only male patients with squamous cell carcinoma. Still, they concluded that “our results suggest that with protocol adjustments, PET/MR imaging may be used clinically for the preoperative staging of esophageal cancer in the future.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.